Search Results - "Kadosh, Shaul"

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial by Bockorny, Bruno, Semenisty, Valerya, Macarulla, Teresa, Borazanci, Erkut, Wolpin, Brian M., Stemmer, Salomon M., Golan, Talia, Geva, Ravit, Borad, Mitesh J., Pedersen, Katrina S., Park, Joon Oh, Ramirez, Robert A., Abad, David G., Feliu, Jaime, Muñoz, Andres, Ponz-Sarvise, Mariano, Peled, Amnon, Lustig, Tzipora M., Bohana-Kashtan, Osnat, Shaw, Stephen M., Sorani, Ella, Chaney, Marya, Kadosh, Shaul, Vainstein Haras, Abi, Von Hoff, Daniel D., Hidalgo, Manuel

“…Programmed cell death 1 (PD-1) inhibitors have limited effect in pancreatic ductal adenocarcinoma (PDAC), underscoring the need to co-target alternative…”
Get full text

Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial by Bockorny, Bruno, Macarulla, Teresa, Semenisty, Valerya, Borazanci, Erkut, Feliu, Jaime, Ponz-Sarvise, Mariano, Abad, David Gutierrez, Oberstein, Paul, Alistar, Angela, Muñoz, Andres, Geva, Ravit, Guillén-Ponce, Carmen, Fernandez, Mercedes Salgado, Peled, Amnon, Chaney, Marya, Gliko-Kabir, Irit, Shemesh-Darvish, Liron, Ickowicz, Debby, Sorani, Ella, Kadosh, Shaul, Vainstein-Haras, Abi, Hidalgo, Manuel

“…Pancreatic ductal adenocarcinoma (PDAC) is largely unresponsive to checkpoint inhibitors. Blockade of the CXCR4/CXCL12 axis increases intratumoral trafficking…”
Get full text

BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study by Borthakur, Gautam, Ofran, Yishai, Tallman, Martin S., Foran, James, Uy, Geoffrey L., DiPersio, John F., Showel, Margaret M., Shimoni, Avichai, Nagler, Arnon, Rowe, Jacob M., Altman, Jessica K., Abraham, Michal, Peled, Amnon, Shaw, Stephen, Bohana‐Kashtan, Osnat, Sorani, Ella, Pereg, Yaron, Foley‐Comer, Adam, Oberkovitz, Galia, Lustig, Tzipi M., Glicko‐Kabir, Irit, Aharon, Arnon, Vainstein‐Haras, Abi, Kadosh, Shaul E., Samara, Emil, Al‐Rawi, Ahmed N., Pemmaraju, Naveen, Bueso‐Ramos, Carlos, Cortes, Jorge E., Andreeff, Michael

“…Background CXCR4 mediates the retention and survival of acute myelogenous leukemia blasts in bone marrow and contributes to their resistance to chemotherapy…”
Get full text

Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study by Ford, Corey C, Cohen, Jeffrey A, Goodman, Andrew D, Lindsey, John W, Lisak, Robert P, Luzzio, Christopher, Pruitt, Amy, Rose, John, Rus, Horea, Wolinsky, Jerry S, Kadosh, Shaul E, Bernstein-Hanlon, Emily, Stark, Yafit, Alexander, Jessica K

“…Background: Glatiramer acetate (GA) is US-approved for relapsing multiple sclerosis. Objectives: To describe GA long-term clinical profile. To compare…”
Get full text

A randomized trial of a low‐dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease by Olanow, C. Warren, Kieburtz, Karl, Leinonen, Mika, Elmer, Lawrence, Giladi, Nir, Hauser, Robert A., Klepiskaya, Olga S., Kreitzman, David L., Lew, Mark F., Russell, David S., Kadosh, Shaul, Litman, Pninit, Friedman, Hadas, Linvah, Nurit, the P2B Study Group, for

“…ABSTRACT Background Rasagiline and pramipexole act to improve striatal dopaminergic transmission in PD via distinct and potentially synergistic mechanisms. We…”
Get full text

Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study by Rieckmann, Peter, Zivadinov, Robert, Boyko, Alexey, Selmaj, Krzysztof, Alexander, Jessica K., Kadosh, Shaul, Rubinchick, Svetlana, Bernstein-Hanlon, Emily, Stark, Yafit, Ashtamker, Natalia, Davis, Mat D., Khan, Omar

“…Objective Describe the long-term outcomes of early-start (ES) and delayed-start (DS) glatiramer acetate 40 mg/mL treatment three times weekly (GA40) for up to…”
Get full text

Higher daily Aramchol dose results in higher effect size in fibrosis improvement in the ARMOR study open label part by Ratziu, Vlad, Yılmaz, Yusuf, Lazas, Don, Friedman, Scott, Hayardeny, Liat, Kadosh, Shaul, Gorfine, Tali, Sanyal, Arun

Get full text

Use of Combination Premedication Prior to Motixafortide Administration Reduced Severity and Frequency of AEs in the Phase 3 Genesis Trial - a Single Center Analysis by Crees, Zachary David, Stockerl-Goldstein, Keith, Schroeder, Mark A., Vij, Ravi, Sorani, Ella, Gliko Kabir, Irit, Goldstein, Inbal, Lustig, Tzipi, Kadosh, Shaul, DiPersio, John F.

“…Background: Motixafortide is a novel, high affinity CXCR4 antagonist with extended receptor occupancy that facilitates the migration of hematopoietic stem and…”
Get full text

Aramchol improves hepatic fibrosis in metabolic dysfunction-associated steatohepatitis: Results of multimodality assessment using both conventional and digital pathology by Ratziu, Vlad, Yilmaz, Yusuf, Lazas, Don, Friedman, Scott L, Lackner, Caroline, Behling, Cynthia, Cummings, Oscar W, Chen, Li, Petitjean, Mathieu, Gilgun-Sherki, Yossi, Gorfine, Tali, Kadosh, Shaul, Eyal, Eli, Sanyal, Arun J

“…Antifibrotic trials rely on conventional pathology despite recognized limitations. We compared single-fiber digital image analysis with conventional pathology…”
Get full text

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial by Crees, Zachary D., Rettig, Michael P., Jayasinghe, Reyka G., Stockerl-Goldstein, Keith, Larson, Sarah M., Arpad, Illes, Milone, Giulio A., Martino, Massimo, Stiff, Patrick, Sborov, Douglas, Pereira, Denise, Micallef, Ivana, Moreno-Jiménez, Gemma, Mikala, Gabor, Coronel, Maria Liz Paciello, Holtick, Udo, Hiemenz, John, Qazilbash, Muzaffar H., Hardy, Nancy, Latif, Tahir, García-Cadenas, Irene, Vainstein-Haras, Abi, Sorani, Ella, Gliko-Kabir, Irit, Goldstein, Inbal, Ickowicz, Debby, Shemesh-Darvish, Liron, Kadosh, Shaul, Gao, Feng, Schroeder, Mark A., Vij, Ravi, DiPersio, John F.

“…Autologous hematopoietic stem cell transplantation (ASCT) improves survival in multiple myeloma (MM). However, many individuals are unable to collect optimal…”
Get full text

Multimodality assessment of hepatic fibrosis: ranked paired reading and artificial intelligence identifies fibrosis improvement with aramchol missed by conventional staging by Ratziu, Vlad, Yılmaz, Yusuf, Lazas, Don, Friedman, Scott, Lackner, Carolin, Behling, Cynthia, Cummings, Oscar, Chen, Li, Petitjean, Mathieu, Gilgun-Sherki, Yossi, Kadosh, Shaul, Sanyal, Arun

Get full text

Immunophenotypic and Single-Cell Transcriptional Profiling of CD34+ Hematopoietic Stem and Progenitor Cells Mobilized with Motixafortide (BL-8040) and G-CSF Versus Plerixafor and G-CSF Versus Placebo and G-CSF: A Correlative Study of the Genesis Trial by Crees, Zachary D., Retting, Michael, Jayasinghe, Reyka G, Stockerl-Goldstein, Keith E., Vainstein, Abi, Sorani, Ella, Ickowicz, Debby, Shemesh-Darvish, Liron, Kadosh, Shaul, DiPersio, John F.

“…▪ Background: CD34 expression remains the most common immunophenotypic cell surface marker defining human hematopoietic stem and progenitor cells (HSPCs)…”
Get full text

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial by Crees, Zachary D., Stockerl-Goldstein, Keith E., Larson, Sarah, Illés, Árpád, Milone, Giuseppe, Martino, Massimo, Stiff, Patrick, Sborov, Douglas W., Pereira, Denise L., Micallef, Ivana N., Moreno Jiménez, Gemma, Mikala, Gábor, paciello Coronel, Maria liz, Holtick, Udo, Hiemenz, John W., Qazilbash, Muzaffar H., Hardy, Nancy M., Latif, Tahir, García-Cadenas, Irene, Vainstein, Abi, Sorani, Ella, Gliko-Kabir, Irit, Goldstein, Inbal, Kadosh, Shaul, DiPersio, John F.

“…Background: Autologous stem cell transplantation (ASCT) in multiple myeloma (MM) has been shown to improve survival compared to conventional chemotherapy…”
Get full text

Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial by Crees, Zachary D., Stockerl-Goldstein, Keith E., Retting, Michael, Larson, Sarah M, Illes, Arpad, Milone, Giuseppe, Martino, Massimo, Stiff, Patrick, Sborov, Douglas W., Pereira, Denise L., Micallef, Ivana N., Moreno Jiménez, Gemma, Mikala, Gábor, Paciello Coronel, Maria Liz, Holtick, Udo, Hiemenz, John W., Qazilbash, Muzaffar H., Hardy, Nancy M., Latif, Tahir, García-Cadenas, Irene, Sorani, Ella, Shemesh-Darvish, Liron, Vainstein, Abi, Kadosh, Shaul, DiPersio, John F.

“…Background: CD34+ hematopoietic stem and progenitor cell (HSPC) dose during hematopoietic cell transplantation (HCT) remains one of the most reliable clinical…”
Get full text

Abstract CT177: A multi-center phase 2a trial of the CXCR4 inhibitor motixafortide (BL-8040) (M) in combination with pembrolizumab (P) and chemotherapy (C), in patients with metastatic pancreatic adenocarcinoma (mPDAC) by Hidalgo, Manuel, Macarulla, Teresa, Semenisty, Valerya, Borazanci, Erkut, Feliu, Jaime, Ponz-Sarvise, Mariano, Abad, David Gutierrez, Oberstein, Paul, Alistar, Angela, Muñoz, Andres, Geva, Ravit, Guillén-Ponce, Carmen, Fernandez, Mercedes Salgado, Peled, Amnon, Chaney, Marya, Glicko-Kabir, Irit, Shemesh-Darvish, Liron, Ickowicz, Debby, Sorani, Ella, Kadosh, Shaul E., Vainstein-Haras, Abi, Bockorny, Bruno

“…Abstract Background: Improving outcomes of PDAC with checkpoint inhibitors (CPIs) have been ineffective, underscoring the need to co-target alternative…”
Get full text

Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups by Jaramillo Segura, Sonia, Wass, Maxi, Schaffrath, Judith, Rieger, Kathrin, Nogai, Axel, Haenel, Mathias, Herbst, Regina, Stoelzel, Friedrich, Röllig, Christoph, Jost, Edgar, Schlenk, Richard F., Noppeney, Richard, Brandts, Christian H., Krug, Utz, Goetze, Katharina S., Buske, Sebastian, Florschütz, Axel, Schubert, Jörg, Opitz, Bernhard, Mohren, Martin, Eßeling, Eva, von Witzendorff, Stephan, Subklewe, Marion, Kaufmann, Martin, Frickhofen, Norbert, Scholz, Christian W, Schäfer-Eckart, Kerstin, Kunzmann, Volker, Schmidt-Hieber, Martin, Sayer, Herbert G., Rank, Andreas, Hemmati, Philipp, Schueler, Frank, Kowoll, Simone, Scheller, Marina, Steighardt, Jörg, Edemir, Bayram, Mueller, Lutz Peter, Gliko-Kabir, Irit, Ludwig-Kraus, Beatrice, Edemir, Sabine, Sorani, Ella, Binder, Mascha, Vainstein, Abi, Kadosh, Shaul, Gromann, Cora, Wienke, Andreas, Baldus, Claudia D., Platzbecker, Uwe, Serve, Hubert, Bornhaeuser, Martin, Junghanss, Christian, Mueller-Tidow, Carsten

Get full text

Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial by Wolinsky, Jerry S., Narayana, Ponnada A., O'Connor, Paul, Coyle, Patricia K., Ford, Corey, Johnson, Kenneth, Miller, Aaron, Pardo, Lillian, Kadosh, Shaul, Ladkani, David

“…Objective To determine whether glatiramer acetate (GA) slows accumulation of disability in primary progressive multiple sclerosis. Methods A total of 943…”
Get full text

Motixafortide Enables Consistent, Robust Hematopoietic Stem Cell Collection (HSC) across Populations with Increased Impaired HSC Mobilization: A Sub-Group Analysis of the Genesis Study by Crees, Zachary D, Rettig, Michael P., Jayasinghe, Reyka, Stockerl-Goldstein, Keith, Larson, Sarah M, Arpad, Illes, Milone, Giuseppe, Martino, Massimo, Stiff, Patrick J., Sborov, Douglas, Pereira, Denise, Micallef, Ivana N, Moreno-Jiménez, Gemma, Mikala, Gabor, Coronel, Maria L Paciello, Holtick, Udo, Hiemenz, John, Qazilbash, Muzaffar H., Hardy, Dr. Nancy Maureen, Latif, Tahir, Garcia-Cadenas, Irene, Vainstein-Haras, Abi, Sorani, Ella, Gliko-Kabir, Irit, Goldstein, Inbal, Ickowicz, Debby, Darvish, Liron, Kadosh, Shaul, Gao, Feng, Schroeder, Mark A., Vij, Ravi, DiPersio, John F.

“…The clinical benefit of autologous hematopoietic stem cell transplant (ASCT) for multiple myeloma (MM) partly depends on the ability to collect sufficient…”
Get full text

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients by Ford, C C, Johnson, K P, Lisak, R P, Panitch, H S, Shifroni, G, Wolinsky, J S

“…A decade of continuous glatiramer acetate (GA) use by relapsing remitting multiple sclerosis (RRMS) patients was evaluated in this ongoing, prospective study,…”
Get full text